News | News By Subject | News by Disease News By Date | Search News

Endometriosis News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
AbbVie (ABBV)'s Elagolix Successful in Second Phase III Study     2/10/2016
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Evotec AG (EVTG.F) and Bayer AG (BAYZF) Enter Into $765 Million Multi-Target Alliance to Fight Endometriosis     10/1/2012
Neurocrine Biosciences, Inc. (NBIX) Phase 2 Endometriosis Drug, Elagolix Meets Goals     5/25/2010
FDA May Lift Hold On Repros Therapeutics Inc. (RPRX)'s Proellex     4/30/2010
Neurocrine Biosciences, Inc. (NBIX)'s Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis     7/29/2009
Repros Therapeutics Inc. (RPRX) Announces that Initial Findings for Proellex(R) Show No Tumorigenic Response in a Two-year Carcinogenicity Study in Rats     7/21/2008
Repros Therapeutics Inc. (RPRX) Says Uterus Drug Significantly Reduces Pain in Trial     7/11/2008
AEterna Zentaris (AEZS) Regains Exclusive Worldwide (ex-Japan) Rights from Solvay for Cetrorelix in Endometriosis Indication     5/8/2007
Repros Therapeutics Inc. (RPRX)'s Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids     4/3/2007
AEterna Zentaris (AEZS) Announces Cetrorelix Development With Solvay Chemicals Inc. Continues With Endometriosis As A Primary Indication     3/16/2005
Columbia Laboratories, Inc. (CBRX) Release: Kronos Longevity Research Institute -KLRI- Changes Protocol For HRT Study     8/16/2004
Spectrum Pharmaceuticals (SPPI) Licenses A Fourth-Generation Phase 2 LHRH Antagonist From Zentaris GmbH (AELA)     8/12/2004

News from Around the Web

Press Releases
Myovant (MYOV) Announces Presentation Of Data At The European Congress Of Endocrinology From Phase ll Extension Study Evaluating Relugolix In Women With Endometriosis-Associated Pain     5/24/2017
Myovant (MYOV) Announces Presentation Of Positive Phase II Data For Relugolix In Women With Endometriosis-Associated Pain At The World Congress On Endometriosis     5/22/2017
AbbVie (ABBV) Presents Pivotal Phase III Data On Investigational Treatment Elagolix At The World Congress On Endometriosis     5/18/2017
Myovant (MYOV) Announces Upcoming Presentations Of Relugolix Data From Phase II Trial In Women With Endometriosis-Associated Pain     5/18/2017
Repros Therapeutics (RPRX) Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex In The Treatment Of Endometriosis     12/20/2016
MDNA Life Sciences And University of Oxford To Collaborate To Develop A Mitochondrial Biomarker Blood-Based Diagnostic For Endometriosis     11/1/2016
Repros Therapeutics (RPRX) Provides Phase II Results Showing Positive Outcomes For Oral Proellex In Women With Moderate To Severe Endometriosis     9/8/2016
Enteris Biopharma Initiates Clinical Program For Tobrate (Oral Tobramycin Tablet) In Uncomplicated Urinary Tract Infection     7/13/2016
Neurocrine Biosciences (NBIX) Reports First Quarter 2016 Results     5/6/2016
AbbVie (ABBV) Initiates Enrollment In Phase 3 Clinical Program For Elagolix In Patients With Uterine Fibroids     1/28/2016
ObsEva And Kissei Pharmaceutical Co., Ltd. Announce Global Agreement To Develop And Commercialize KLH-2109 For The Treatment Of Endometriosis     11/20/2015
AbbVie (ABBV), Neurocrine Biosciences, Inc. (NBIX) Drug Successful in Late Stage Endometriosis Trial     1/8/2015
Repros Therapeutics Inc. (RPRX) Allowed To Conduct Phase 1 And 2 Clinical Studies Of Low Dose Oral Proellex® In The Treatment Of Uterine Fibroids And Endometriosis     3/18/2014
Repros Therapeutics Inc. (RPRX) Allowed To Conduct Phase 1 And 2 Clinical Studies Of Low Dose Oral Proellex® In The Treatment Of Uterine Fibroids And Endometriosis     3/17/2014
AmorChem l.p., Universite Laval And CHU De Quebec Collaborate On The Development Of A Treatment For Endometriosis And Estrogen-Dependent Cancers     12/19/2013